| Document |
Document Title |
|
JP2024509760A |
As used herein, formula (A'): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein1,X2,X3,X4,Ra,Rb,Rc, L, Q, and Y are as defined herein. Also provided are methods of inhibiting AP...
|
|
JP2024508047A |
The present disclosure includes, among other things, lipids, compositions, and methods useful for delivering polynucleotides or oligonucleotides, such as viral genomes.
|
|
JP7436370B2 |
Disclosed are a quaternary ammonium salt compound, a preparation method therefor and a use thereof. Provided is a novel structural compound as shown in formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, ...
|
|
JP2024506365A |
Benzazepine compounds, their preparation methods, and pharmaceutical uses. Specifically, the present invention relates to a compound represented by formula II-1 or formula VIII-1, a pharmaceutical composition containing the same, and a p...
|
|
JP7428647B2 |
The present invention relates to 5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepine derivatives of general formula (I) and/or salts thereof and/or geometric isomers thereof and/or stereoisomers thereof and/or enantiomers thereof and/or ...
|
|
JP2024503753A |
Compounds, compositions, and methods for treating neurological and mitochondrial diseases are disclosed. [Selection diagram] None
|
|
JP2024007310A |
An object of the present invention is to provide a method for purifying recovered ε-caprolactam in which the loss rate of recovered ε-caprolactam is sufficiently low even though crystallization is performed in an aqueous solvent. [Solu...
|
|
JP2023552792A |
The present invention provides immunoconjugates of Formula I comprising an anti-HER2 antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The present invention also provides 8-Het-2-aminobenzazepine derivat...
|
|
JP7400993B2 |
Provided is a green, energy-saving production method that achieves both re-utilization of a fossil resource and reduction of greenhouse gas emissions in a method for producing ε-caprolactam from a polyamide 6 resin composition. The pres...
|
|
JP2023546527A |
Benzazepine spirocyclic derivatives represented by formula (I) and pharmaceutically acceptable salts thereof, these compounds are used for diagnosing, preventing and/or treating diseases associated with vasopressin receptors . [Formula 1]
|
|
JP2023546100A |
Glutamine analogs, compositions containing glutamine analogs and uses thereof.
|
|
JP2023134629A |
To provide a radiolabeled ligand for use in the diagnosis of NMDA receptor-associated diseases or disorders by positron emission tomography (PET), single-photon emission computed tomography (SPECT), liquid scintillation count assay, or a...
|
|
JP2023540661A |
The present invention provides compounds of formula (I) as CCR8 inhibitors, which can be used to treat or prevent cancer using CCR8 inhibitors that target tumor-specific regulatory T cells. can be done. Formula (I): [Selection diagram] None
|
|
JP2023538842A |
[Solution] The present invention contains monomeric diphenylmethane diisocyanate (MDI) as component (q1), and an amide with a molecular weight of less than 200 g/mol as component (q2), the total of components (q1) and (q2) being 100% by ...
|
|
JP2023537630A |
The present disclosure relates to compounds of formula (I) and their prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods of preparation thereof. The compounds disclosed herein a...
|
|
JP7334871B1 |
Disclosed is a green and energy-saving method for producing ε-caprolactam from a polyamide 6 resin composition, which achieves both recycling of fossil resources and reduction of greenhouse gas emissions. The present invention provides ...
|
|
JP7327839B2 |
The present invention relates to a tetrahydro-1H-benzazepine compound as potassium channel modulator, a preparation method and a use thereof. Specifically, the compound of the present invention has the structure shown by formula A, where...
|
|
JP7312891B2 |
The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial inhibitors called mitoriboscins—mitoch...
|
|
JP2023099166A |
To provide a novel method for preparing caprolactam from 6-aminocaproic acid (hereafter called 6-ACA) obtained in a biochemical process, and in particular such a method that allows a satisfactory caprolactam yield.The invention provides ...
|
|
JP2023528624A |
The present invention relates to novel intermediates for the synthesis of tolvaptan and its derivatives and processes for their preparation, including said intermediates.
|
|
JP2023527501A |
The present invention disclosed a novel purely inorganic solid silylsulfonic acid and/or phosphoric acid catalyst material preparation method and its application. Using metasilicic acid rich in hydroxyl groups on the surface as a raw mat...
|
|
JP2023523213A |
The present invention provides an isolated material, or at least one phenol-containing active material in phenolate form, wherein the isolated material comprises one or more phenolate species and a counterion in the form of a metal salt,...
|
|
JP2023522058A |
The present invention discloses benzonitric heterocyclic compounds, methods of making and uses thereof. The present invention provides benzodiazepines of formula I, which can be used as histone deacetylase inhibitors, have selective inhi...
|
|
JP7279758B2 |
A compound shown by general formula (I-1) (in the formula, all symbols are as stated in the specification.) has selective S1P5 receptor-binding activity. Adjusting this activity make s it possible to obtain a therapeutic agent for S1P5-m...
|
|
JP2023520367A |
[Theme] Kind Code: A1 Various embodiments of the present disclosure are directed to compounds having Formula 1, Formula 1A, Formula 1B, Formula 1C, Formula 1D, and Formula 1E, and pharmaceutically acceptable salts thereof. The compounds ...
|
|
JP2023518027A |
The present disclosure provides, inter alia, compounds that modulate GPX4 activity. Pharmaceutical compositions containing the compounds are also provided. Further, methods of treating or ameliorating the effects of cancer in a subject, ...
|
|
JP2023044549A |
To provide a water treatment system and a water treatment method for treating water at low energy.A water treatment system has: a first vessel accommodating a mixed solution of treated water and an amine solution containing one or more t...
|
|
JP7244134B2 |
[Problem] To provide a novel means capable of generating highly stereoselective and/or highly efficient amidation reactions in a variety of substrates having a carboxyl group and an amino group, and capable of producing amide compounds.[...
|
|
JP7241825B2 |
The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
|
|
JP7235742B2 |
The present invention relates to compounds of formula (I):wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...
|
|
JP2023508872A |
A method for producing N-vinyl compounds by homogeneous catalysis, comprising reacting acetylene with at least one nitrogen atom in the liquid phase in the presence of a ruthenium complex containing at least one phosphine as a ligand (Ru...
|
|
JP7229482B2 |
An object of the invention is to develop a group of new compounds with inhibitory activity against the function of Pin1 as candidate compounds for drugs.The present invention provides compounds represented by the following Formula (I) or...
|
|
JP7228588B2 |
The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors. The present invention also relates to p...
|
|
JP7227741B2 |
The present invention provides novel fluorescent dyes and kits containing the same, which are useful for labeling a wide variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the ...
|
|
JP2023506663A |
A method of preparing a mixture comprising cyclohexanol and cyclohexanone comprising the step of hydrogenating cyclohexyl hydroperoxide in cyclohexane in the presence of a Raney nickel catalyst to obtain cyclohexanol and cyclohexanone.
|
|
JP2023506172A |
A method for the synthesis of N-alkylated lactams via reductive alkylation. The method of the present disclosure can be carried out by adding an aldehyde to a lactam in the presence of a catalyst in a reducing atmosphere.
|
|
JP7218005B2 |
An object of the present invention is to provide a novel tetrahydroazepine compound and a process for producing the same. The present invention relates to a tetrahydroazepine compound represented by the formula (10) or a salt thereof, an...
|
|
JP7217712B2 |
A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention a...
|
|
JP7215421B2 |
Provided is a method for producing a pentenoic acid ester derivative using a biomass raw material, comprising step A for reacting the biomass raw material with a first alcohol in the presence of an acid catalyst to obtain a levulinic aci...
|
|
JP2023501620A |
The present invention relates to compounds of formula (I) or their stereoisomers, or salts of any of the foregoing, and processes for their preparation. Compounds of formula (I) are useful for treating TRPML1-mediated disorders or diseases.
|
|
JP2023501000A |
The present disclosure provides the 3-(4-(11H-dibenzo[b,e][1,4] Azepin-6-yl)piperazin-1-yl)-propanoic acid derivative, 3-(4-(dibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-yl)-propan
oic acid derivative , 3-(4-(dibenzo[b,f][1,4]thiazepin-11...
|
|
JP7186994B2 |
An object of the present invention is to provide a novel tetrahydroazepine compound and a process for producing the same. The present invention relates to a tetrahydroazepine compound represented by the formula (10) or a salt thereof, an...
|
|
JP2022551198A |
Compounds of Formula I(I), or pharmaceutically acceptable salts thereof, wherein the substituents are as defined herein, are described. Pharmaceutical compositions containing the compounds and methods of using them are also described. [C...
|
|
JP2022551197A |
Compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein the substituents are as defined herein, are described. Pharmaceutical compositions containing such compounds and methods of using same are also described. [Ch...
|
|
JP7185633B2 |
The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or method...
|
|
JP2022550640A |
Compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein the substituents are as defined herein, are described. Pharmaceutical compositions containing the compounds and methods of using them are also described. [Che...
|
|
JP2022548594A |
The present invention provides compounds, compositions thereof, and methods of use thereof for the inhibition of USP30 and the treatment of USP30-mediated disorders.
|
|
JP2022169758A |
To provide a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof.The invention provides a compound represented by the formula (1) in the fig...
|
|
JP7167021B2 |
Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L1 and L2 are each independently a covalent bond or a divalent linking group, R is a detectable label or therapeutic drug and B is an alb...
|
|
JP7149073B2 |
The present invention describes compounds and uses thereof in applications relating to absorption of electromagnetic energy. Preferred compounds are double bond-containing compounds capable of absorbing electromagnetic radiation energy a...
|
